Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 435,984
  • Shares Outstanding, K 63,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,640 K
  • 60-Month Beta -0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade EWTX with:

Options Overview Details

View History
  • Implied Volatility 86.18% ( -5.94%)
  • Historical Volatility 64.83%
  • IV Percentile 66%
  • IV Rank 64.67%
  • IV High 131.23% on 03/10/23
  • IV Low 3.73% on 08/22/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 205
  • Open Int (30-Day) 300

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.42
  • Low Estimate -0.50
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -45.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.12 +36.13%
on 11/10/23
7.34 -5.01%
on 12/08/23
+0.80 (+12.97%)
since 11/08/23
3-Month
5.12 +36.13%
on 11/10/23
7.69 -9.36%
on 10/06/23
+0.70 (+11.16%)
since 09/08/23
52-Week
5.12 +36.13%
on 11/10/23
11.48 -39.29%
on 01/17/23
-1.43 (-17.02%)
since 12/08/22

Most Recent Stories

More News
Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 6.97 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 7.85
2nd Resistance Point 7.59
1st Resistance Point 7.28
Last Price 6.97
1st Support Level 6.71
2nd Support Level 6.46
3rd Support Level 6.15

See More

52-Week High 11.48
Fibonacci 61.8% 9.05
Fibonacci 50% 8.30
Fibonacci 38.2% 7.55
Last Price 6.97
52-Week Low 5.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar